Skip to main content

Advertisement

Table 5 Adjusted odds ratios and 95% CI for interactions between injection with a used syringe and the IDU risk network variables.

From: Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada

   Reported injection with used syringe
A)    
   Yes No
Number of talwin/ritalin users in IDU risk network 0 7.9 (3.7–16.8) 95 HCV +/58 HCV - (62%) 1.00 24 HCV +/81 HCV - (22.9%)
  1–3 0.6 (0.3–42.4) 26 HCV +/10 HCV - (72%) 1.00 16 HCV +/7 HCV - (69.6%)
  4–5 1.0 (0.2–156.8) 28 HCV +/9 HCV - (76%) 1.00 9 HCV +/2 HCV - (81.8%)
B)    
   Reported injection with used syringe
   Yes No
Number of IDU who have shown the respondent how to inject drugs 0 7.9 (3.7–16.8) 111 HCV +/41 HCV - (73.0%) 1.00 36 HCV +/63 HCV - (36.4%)
  1 7.7 (0.3–37.1) 31 HCV +/23 HCV - (57.4%) 1.00 8 HCV +/20 HCV - (28.6%)
  2–5 0.4 (0.2–87.2) 7 HCV +/13 HCV - (33.3%) 1.00 5 HCV +/7 HCV - (41.6%)
  1. (A) number of IDU in the network who used talwin/ritalin or (B) have shown the respondent how to inject. Serostatus data for HCV corresponding to each cell is also shown.